Pieris Pharmaceuticals (PIRS) Lowered to Hold at ValuEngine
Other equities research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Pieris Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a report on Thursday, March 21st. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Pieris Pharmaceuticals in a report on Tuesday, March 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $4.25.
PIRS traded down $0.17 during trading hours on Thursday, reaching $3.39. 274,116 shares of the stock traded hands, compared to its average volume of 363,243. The firm has a market cap of $174.97 million, a price-to-earnings ratio of -6.78 and a beta of 1.88. Pieris Pharmaceuticals has a fifty-two week low of $2.39 and a fifty-two week high of $6.94.
A number of hedge funds have recently made changes to their positions in the business. Massachusetts Financial Services Co. MA grew its holdings in Pieris Pharmaceuticals by 8.4% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 70,498 shares of the biotechnology company’s stock worth $187,000 after acquiring an additional 5,487 shares in the last quarter. SG Americas Securities LLC acquired a new position in Pieris Pharmaceuticals during the 4th quarter worth $36,000. Prudential Financial Inc. acquired a new position in Pieris Pharmaceuticals during the 4th quarter worth $43,000. Alambic Investment Management L.P. acquired a new position in Pieris Pharmaceuticals during the 4th quarter worth $59,000. Finally, Rhumbline Advisers grew its holdings in Pieris Pharmaceuticals by 51.5% during the 4th quarter. Rhumbline Advisers now owns 66,836 shares of the biotechnology company’s stock worth $178,000 after acquiring an additional 22,720 shares in the last quarter. 70.73% of the stock is owned by institutional investors.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Recommended Story: Backdoor Roth IRA Conversion and Strategy
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.